سعر ماتروكوند0.03% قطرة عين 2022

Bimatoprost 0.03% sterile ophthalmic solution (3 ml) by Sigma Tec / Concord Pharmaceutical Industries, Egypt, for lowering intraocular pressure.

• Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most frequent (about 15-45%): conjunctival hyperaemia, eyelash growth and ocular pruritus; about 3-10%: ocular dryness, visual disturbance, burning, foreign body sensation, eye pain, periocular skin pigmentation, blepharitis, cataract, superficial punctate keratitis, periorbital erythema, ocular irritation and eyelash darkening; about 10% had systemic infections (mainly colds and upper respiratory infections).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Post-marketing: abnormal hair growth, asthma-like symptoms, dizziness, dyspnoea, eyelid oedema, hypersensitivity, hypertension, nausea, periorbital fat atrophy-related lid changes (deepened sulcus, ptosis, enophthalmos) and non-periocular skin discoloration.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to bimatoprost or to any of the ingredients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• May increase brown pigmentation of the iris, eyelid skin and eyelashes; iris pigmentation is likely to be permanent, eyelid and lash changes may be reversible.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• May gradually increase the length, thickness and number of eyelashes and vellus hair in the treated eye; usually reversible after stopping.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use with caution in active intraocular inflammation (e.g. uveitis), as prostaglandin analogues may cause or exacerbate inflammation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; postmarketing experience shows no increased risk of major birth defects or miscarriage; abortion and early delivery occurred in animals at high oral exposures; use in pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not known whether ocular use gives detectable amounts in human milk; bimatoprost is present in rat milk; weigh the benefits of breastfeeding against the mother's clinical need and possible effects on the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Bimatoprost: Synthetic prostaglandin analogue that mimics prostamides; believed to lower intraocular pressure by increasing aqueous humour outflow through both the trabecular meshwork and uveoscleral routes.